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Abstract
Background: Selection of specific patient-reported outcomes (PROs) for cancer patients requires careful
consideration to the purpose and population at aim. Here we report the process of choosing which items
to include in a bladder cancer population in chemo- or immunotherapy based on the Patient-Reported
Outcomes Version of the Common Terminology Criteria of Adverse Events (PRO-CTCAE).
Methods: Initial PRO-CTCAE symptoms were chosen through 1) medical record audit 2) patient interviews
3) summary of product characteristics from European Medicines Agency and Food and Drug Administration
for the applied chemotherapies, and 4) toxicity reporting from Phase 2 and 3 trials for immunotherapies
applied in patients with urothelial cancer. The selected questions were applied in a prospective cohort of
78 bladder cancer patients receiving chemo- or immunotherapy at Rigshospitalet and Herlev Hospital,
Denmark. Symptoms tested in this population were selected for the final module if they appeared in ≥3 of
the following groupings a) the most prevalent PRO-CTCAE symptoms grade ≥ 2 overall during treatment b)
the PRO-CTCAE symptoms reported in conjunction with hospital admissions or mentioned in focus group
interviews discussing which symptoms were prevalent in this patient group with specialized c) nurses or d)
physicians. The authors also included symptoms in the final module if they were present in two of the
above groups and defined as actionable by clinicians.
Results: From the initial selection of PRO-CTCAE symptoms, a total of 45 PRO-CTCAE symptoms explored
by 84 PRO-CTCAE questions were retrieved. Through the second selection process based on the described
criteria, the study group agreed on 15 PRO-CTCAE symptoms explored by 30 PRO-CTCAE items to be
appropriate and relevant for the bladder population during medical oncological treatment.
Conclusions: The selection of disease specific PROs in a bladder cancer population was feasible. The
process revealed several steps of selection needed in order to reach a final module for clinical application.
Keywords: Patient-reported outcomes, Item selection, Bladder cancer, Chemotherapy, Immunotherapy
Background
For decades toxicity monitoring during treatment for
cancer has been a priority in clinical cancer care
practice. The Common Terminology Criteria of Ad-
verse Events (CTCAE) has enabled uniform clinician
reporting of toxicities across clinical trials and coun-
tries [1]. However, an increasing body of literature
informs us of the incongruence between patient and
clinician reporting. The clinician typically underscores
the symptomatic adverse events of the patient thereby
underestimating the effect a given symptom has on
the patient’s life [2, 3]. To overcome this gap between
patient and clinician, the National Cancer Institute
(NCI) in the US developed the Patient-Reported Out-
comes version of Common Terminology Criteria of
Adverse Events (PRO-CTCAE) as a supplement to
regular toxicity monitoring [4]. The introduction of
patient-reported outcomes (PROs) in cancer care as a
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proactive symptom management tool has in clinical
trials shown to be statistically and clinically advanta-
geous for the patient in terms of better quality of life
and even survival [5–9]. Since 2009 the US Food and
Drug Administration (FDA) has advocated for the in-
corporation of PROs in clinical trials [10]. Despite the
FDA recommendation, the NCI initiative and the
reporting of clinical benefits, the use of the PRO-
CTCAE or other PRO tools for symptom monitoring
is not a standard along with the CTCAE reporting in
daily clinical practice. The reasons for this may be
multiple. One of the reasons, as hypothesized by the
authors, may be hesitation and awareness of choosing
the right questions to ask [11]. A given collection of
items may rule out other items that for some patients
are central. Important to have in mind is the aim of
applying PROs, thus defining a subset of questions
crucial for timely capture of progressing symptoms
important to the aim. Questions relevant for captur-
ing early relapses in a survivorship setting may be
different from the questions relevant for sustaining an
acceptable quality of life during treatment. The ques-
tions will therefore differ depending on the popula-
tion at hand hence requiring careful thought and
knowledge of both population and aim. The process
of defining which questions to ask may therefore
delay the implementation of PROs across cancer
diseases. For cancer patients with comorbidities and
limited treatment options implementation of PROs
can be a safe and toxicity-free way of improving
survival [5, 9]. One such population is bladder cancer pa-
tients known to deal with several comorbidities [12, 13].
Patients with muscle-invasive disease (T2-) or metas-
tases have poor clinical outcomes [14–16] and comor-
bidities trouble treatment completion thus impairing
prognosis. We have in a previously conducted study
observed that 31% of bladder cancer patients experi-
ence symptomatic toxicities leading to hospital admis-
sions or discontinuation of treatment (24%) [17].
Patient-reported outcomes may increase patient
awareness towards symptoms and their management,
thereby affecting treatment adherence and in this way
be an option for these patients to improve clinical
outcomes.
The aim of this study was to define the relevant
PRO-CTCAE items for a PRO instrument applicable
in a population of bladder cancer patients in medical
oncological treatment. The final PRO instrument was
planned to be applied in a randomized trial
(NCT03584659) with co-primary endpoints of increas-
ing completion of treatment and reducing hospital ad-
missions by intervening with this PRO instrument
thus allowing for application of the described
methods in other cancer populations.
Methods
Data was collected in two stages in this mixed-methods
study, applying the results of stage 1 in the methods of
stage 2 (see below). The methods applied were inspired
by Nissen et al. [11] and comprised medical record
audit, patient interviews, literature and medical author-
ities document review, prospective collection of PROs in
a clinical setting and analysis hereof and focus group
interviews.
The two stages covered the following and are graphic-
ally displayed in Fig. 1:
1. Stage:
a. Pilot study:
i. Medical record audit
ii. Patient interviews
iii. Summary of Product Characteristics for the
applied chemotherapies (see text below)
iv. Reported adverse events from Phase 2 and 3
clinical trials of immunotherapy in this
population
2. Stage
a. Study 1: Prospective study in the bladder cancer
population with collection of PROs and clinical
outcomes
b. Study 2: Prospective study in the bladder cancer
population with collection of PROs and focus
on the feasibility of electronic reporting
c. Study 3: Focus group interviews
i. Nurses
ii. Physicians
The first stage applied methods introduced by Nissen
et al. [11] and included a pilot study for initial item
selection:
Pilot study
Initial selection of PRO-CTCAE items by a process of i)
medical record audit was performed until data saturation
from 21 consecutive patients receiving chemotherapy for
urothelial cancer at Rigshospitalet, Denmark, from Janu-
ary 2017 to April 2017 noting all symptoms documented
by physician/nurse during the treatment ii) patient inter-
views with patients receiving chemotherapy (combin-
ation cis- or carboplatin and gemcitabine, or single
agent vinflunine) for urothelial cancer until data satur-
ation noting all symptoms mentioned by the patient
without regard to severity or frequency. The patients
were all asked the same questions according to a prede-
fined questionnaire set and were all informed about the
purpose of the interview iii) Summary of Product Char-
acteristics from European Medicines Agency (EMA) and
Food and Drug Administration (FDA) for the applied
chemotherapies (as mentioned above) noting all
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symptoms with a frequency of ≥10% of patients iv) tox-
icity-reporting from Phase 2 and 3 clinical trials of PD1/
PDL-1 inhibitors (as this period came prior to marketing
of immunotherapies for urothelial cancer, no FDA or
EMA Summary of Product Characteristics were avail-
able) [18, 19].
All symptoms, regardless of frequency or severity from
interviews and medical record audit, from the above
process 1a, i-iv, were listed systematically by Medical
Dictionary for Regulatory Activities (MedDRA) and
aligned with the possible corresponding PRO-CTCAE
items thus comprising the initial selection of PRO-
CTCAE questionnaire frame (PRO-CTCAE QF1). This
initial process is listed in Additional file 1 and graphic-
ally displayed in Fig. 1.
For the second stage, the results of the pilot study were
applied in two prospective clinical studies. The results of
these studies were combined with focus group interviews
to conclude the final selection:
Study 1. Patient-reported outcomes and clinical outcomes
Prospective clinical study of 30 patients receiving
chemotherapy (combination cis- or carboplatin and
gemcitabine, or single agent vinflunine) at Rigshospi-
talet, Denmark, for urothelial cancer (with locally ad-
vanced, recurrent or metastatic disease) reporting
quality of life (QoL) and selected patient-reported
outcomes. All patients reported the following ques-
tionnaires weekly electronically or by paper: EORTC
QLQ-C30, EORTC QLQ-BLM30, HADS, PRO-
CTCAE QF1 and 3 general health questions, a total
of 161 questions weekly by each patient throughout
the course of chemotherapy. The study period was
August 2017 – August 2018. Reporting ceased when
terminating treatment, for whatever reason, or if the
patient withdrew consent. Clinical data for all patients
were documented: completion of treatment, reason
for discontinuation of treatment, hospital admissions
and reasons for these. Results from this study have
been reported in a separate paper [17]. For the
current study all PRO-CTCAE symptoms grade ≥ 2
(regardless of which PRO-CTCAE item (frequency, se-
verity, interference with daily activities) were scored
grade ≥ 2, PRO-CTCAE scale is 0–4) throughout the
course of chemotherapy and in relation to all hospital
admissions were listed.
Fig. 1 Item Selection Process. legend: *Rosenberg et al., Lancet 2016, Bellmunt et al., NEJM, 2017
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Study 2: feasibility of electronic reporting in a co-morbid
population
Prospective clinical study of 49 patients with locally
advanced, recurrent or metastatic disease receiving
chemo- (combination cis- or carboplatin and gemcita-
bine, or single agent vinflunine) or immunotherapy
(pembrolizumab) and reporting symptoms and QoL by
the same questionnaire frame as in study 1, weekly
throughout the course of treatment. All patients in this
study completed weekly reporting electronically and the
study was carried out at two university hospitals, Rig-
shospitalet and Herlev Hospital. The study period was
February 2018 – January 2019. The purpose of this study
was primarily testing of feasibility of electronic reporting
and enrolment at two oncological centres prior to initi-
ation of the planned randomized trial. For the current
study, all PRO-CTCAE symptoms grade ≥ 2 data in con-
junction with hospital admissions (completed question-
naires within one week of day of admission to hospital
as the PRO-CTCAE questionnaire time frame is one
week) for patients receiving chemo- or immunotherapy
were retrieved.
Study 3: focus group interviews
Two focus group interviews were conducted, with special-
ist uro-oncological nurses (n = 3) and physicians (n = 4),
separately. Only eligibility criterium was > 2 years of clin-
ical experience with bladder cancer patients. The focus
groups took place in August 2018. Both groups were
asked to list symptoms experienced by the group of
urothelial cancer patients, regardless of relation to treat-
ment, and both groups were posed the same questions
regarding the patient group by author GAT. Both focus
group interviews were recorded and followingly tran-
scribed. All symptoms from these interviews were listed,
irrespective of frequency or severity. No upper limit in
length of the interviews was predefined and the clinicians
were encouraged to talk about the subject until group
agreement on saturation of data.
Symptoms extracted from stage 2 (studies 1–3) above
were listed in four columns, as displayed in Table 1 and
Fig. 1. All symptoms mentioned in three or more col-
umns were included in the final questionnaire frame.
Symptoms mentioned in two columns were included if
the given symptom was preventable/treatable or in some
way could be handled by clinical staff, as evaluated by
the study group. This final selection process was con-
ducted by the study group in October 2018.
Results
In the initial pilot study, the four processes, i-iv, revealed
a total of 84 symptoms, listed by Medical Dictionary for
Regulatory Activities (MedDRA) system organ class.
These 84 symptoms corresponded to 45 PRO-CTCAE
symptoms explored by 84 PRO-CTCAE items, as many
PRO-CTCAE symptoms are explored by single items on
frequency, severity and interference with daily activities.
The symptoms not corresponding to a PRO-CTCAE
symptom were found not to do so primarily because of
the symptom not being assessable by the patient her/
himself, e.g. hyponatremia. As an example, hyponatremia
is easily documented in the summary of product charac-
teristics of a given drug, but more difficultly defined by
symptomology as e.g. confusion, weakness, shivers, nau-
sea or deliria could be present all at once or as single
symptoms and thus detectable by the patient and report-
able by other more comprehensive PRO-CTCAE symp-
toms/items. The results of the pilot study are listed in
Additional file 1. The 84 PRO-CTCAE items were de-
fined to be included in study 1 and study 2.
For study 1, 31 patients were approached and asked to
participate. Only one patient declined participation due
to lack of energy. For study 2, 58 patients were
approached and 49 accepted enrolment. The nine pa-
tients declining participation were either not comfort-
able with the IT solution (n = 2) or did not want to
spend time replying to questionnaires (n = 7). The demo-
graphics for patients participating in study 1 and 2 aligns
well with previous literature, see Table 1 [16]. The clin-
ical course of these patients and reporting of quality of
life have been reported in a separate paper [17]. The
overall questionnaire completion rate was high (Study 1:
71%, Study 2: 75%) with a declining tendency over time.
The extraction of all reported PRO-CTCAE symptoms
grade ≥ 2 from study 1 resulted in a list of 34 PRO-
CTCAE symptoms, listed in falling frequency in Table 2.
Likewise, by extraction of the grade ≥ 2 PRO-CTCAE
symptoms in relation to hospital admissions in study 2
resulted in 21 PRO-CTCAE symptoms, aligned in Table
2 with the results from study 1.
The focus group interviews in study 3 had a duration
of 30–45 min. All mentioned symptoms during the focus
groups were included and resulted in eight symptoms
included from the focus group interview with specialist
nurses and 16 symptoms from the focus group with uro-
oncologists. All symptoms yielded from study 1–3 in
stage two are listed and aligned in Table 2.
Through the selection process described in the
methods section a total of 15 PRO-CTCAE symptoms
explored by 30 PRO-CTCAE questions were selected for
weekly reporting in the planned randomized trial. Illus-
trating an example of this process is the PRO-CTCAE
item on chills which was only present in two out of four
of the defined columns in Table 2. This symptom was
however found manageable by clinicians as a possible
sign of fever and infection and therefore included in the
final set despite only being present in two columns. To
restrain the amount of questions two exceptions to the
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inclusion criteria above were made to this framework;
regarding the PRO-CTCAE item on taste changes that
was mentioned in three of four columns in Table 2.
However, the study group found this item irrelevant for
weekly reports and thereby possible weekly interventions
in the following randomized trial. Also, the PRO-
CTCAE item on abdominal pain was by the study group
found to be covered by the PRO-CTCAE item on gen-
eral pain and was therefore not included in the final set
of PRO-CTCAE symptoms. No further adjustments were
made to limit the volume of the final questionnaire after
going through the processes described above.
The final PRO-CTCAE symptoms included are
marked with bold font in Table 2 and consist of fre-
quent urination, fatigue, nausea, decreased appetite,
pain, shortness of breath, constipation, swelling, insom-
nia, heart palpitations, chills, anxiety, itching, vomiting
and diarrhea.
No data from non-responders was available since the
reasons for non-response typically were deterioration of
performance status, hospital admissions or death.
Discussion
We identified 15 symptoms to be explored weekly by 30
single PRO-CTCAE items among bladder cancer pa-
tients in oncological treatment when applying PRO-
CTCAE items on frequency, severity and/or interference
with daily activities, as validated by the National Cancer
Institute. The framework of this selection process is an-
ticipated transferable to other cancer populations and
the authors encourage application of these methods in
future item selection processes.
A similar systematic approach to the selection process
of PRO-CTCAE items has recently been published by
Trask et al. [20]. The focus is here the selection of PRO-
CTCAE items for industry-sponsored clinical trials thus
considering e.g. consensus decisions from industry-based
working groups. Trask et al. sketch a case example of item
selection for a phase 3 trial in metastatic castrate-resistant
prostate cancer, not too unfamiliar to the bladder cancer
population [20]. This multi-layered selection process is
not unlike the process proposed in the present study,
however, due to the aim in industry-sponsored trials little
attention is paid to the patients’ and caregivers’ perspec-
tives. This discrepancy in methods between Trask and the
present study illustrates clearly the importance in choice
of methods relevant to the aim and population as men-
tioned initially. Especially this is relevant when applying
PROs for proactive symptom management with the aim
of improving HRQOL (health-related quality of life) or
overall survival. Application of a given set of PROs devel-
oped for capture of e.g. symptoms related to cessation of
treatment or hospital admissions in a population of blad-
der cancer patients may not have the desired effect in a
different cancer population (or even the same population)
if the aim is increasing quality of life. Much alike, we
would not apply the same oncological treatment to blad-
der and breast cancer patients and expect the same out-
come. The objective of this study was, besides the
selection of relevant items for a specific population, to de-
scribe the process to enable further implementation in
similar studies or even in clinical practice. Thus, involve-
ment of patients and clinicians may secure greater success
when looking to daily clinical implementation. This idea is
supported by Schmidt et al. who describes a process, simi-
lar to the current, of both patient and clinician involve-
ment in six focus groups (n = 39 health care providers)
and by clinical testing (n = 71 patients) with the precise
aim of implementation in oncological clinical practice.
Schmidt et al. found the involvement of patients and
health care providers essential for suitable and appropriate
selection of PROs and even discovered heterogeneity
Table 1 Patient characteristics from study 1 and 2
Clinical data Total
n = 79 (%)
Study 1
N = 30 (%)
Study 2
n = 49 (%)
Gender Men 64 (81%) 22 (73%) 42 (86%)
Women 15 (19%) 8 (27%) 7 (14%)
Median age, yrs. (range) 68 (35–82) 68 (35–82) 68 (48–80)
Stage Locally advanced 26 (33%) 13 (43%) 13 (27%)
Metastatic 53 (67%) 17 (57%) 36 (73%)
Treatmenta Cisplatin + gemcitabine 46 (59%) 22 (76%) 24 (49%)
Carboplatin + gemcitabine 9 (11%) 6 (21%) 3 (6%)
Vinflunine 3 (4%) 1 (3%) 2 (4%)
Pembrolizumab 20 (26%) 0 (0%) 20 (41%)
Admission to hospital No 32 (41%) 10 (34%) 22 (45%)
Yes 46 (59%) 19 (66%) 27 (55%)
aOne patient in study 1 never started treatment due to cerebral stroke before initiation of treatment
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Table 2 Final PRO-CTCAE Item Selection Process
Focus group interviews Overall PRO-CTCAE
symptoms grade 2-4 for
29 patients* (listed by
falling frequency, %)
PRO-CTCAE symptoms
grade 2-4 in relation
to hospital admission
(patients receiving
n=13 chemo- / n=7
immunotherapy)**
Final included
PRO-CTCAE
symptom
Nurses, n=3 Doctors, n=4
Urinary symptoms Urinary symptoms/catheter problems/infections Frequent urination (48) Frequent urination (2) Frequent urination
Fatigue Fatigue Fatigue (36) Fatigue (9) Fatigue
Urinary urgency (30)
Dry mouth (25) Dry mouth (2)
Nausea Nausea Nausea (22) Nausea (4) Nausea
Pain Pain General pain (22) General pain (7) Pain
Decreased appetite Decreased appetite Decreased appetite (21) Decreased appetite (4) Decreased appetite
Swelling Swelling Swelling (21) Swelling (5) Swelling
Insomnia Insomnia (20) Insomnia (5) Insomnia
Shortness of breath Shortness of breath (19) Shortness of breath (5) Shortness of breath
Constipation Constipation (15) Constipation (1) Constipation
Abdominal pain Abdominal pain (15) Abdominal pain (5)
Sad (15)
Heart palpitations Heart palpitations (14) Heart palpitations (1) Heart palpitations
Painful urination (13)
Muscle pain (12) Muscle pain (3)
Taste changes Taste changes (12) Taste changes (3)
Decreased libido (11)
Urinary incontinence (11)
Diarrhea Diarrhea (11) Diarrhea (4) Diarrhea
Chills (11) Chills (1) Chills
Cough (10)
Headache (10)
Neuropathy Numbness & tingling (9)
Dry skin (9) Dry skin (1)
Discouraged (8)
Ringing in ears (8)
Itching (7) Itching (1) Itching
Anxiety Anxious (6) Anxious
Dizziness (5)
Difficulty swallowing (5)
Increased sweating (4)
Mouth /throat soars (4)
Joint pain (4) Joint pain (1)
Heartburn (3)
Blurred vision (3)
Hair loss (3)
Hot flashes/flushes (2)
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across participating centres hence recommending interdis-
ciplinary focus groups in each setting [21].
Strengths of this study include the mixed methods de-
sign allowing contributions from all stakeholders, patients
or clinicians. Without patient and clinician involvement,
the final questionnaire frame may not be comprehensive
for daily use and implementation. Also, the duration of
this process stretching over 22months enabled thorough
conduction of each step of the process. This gradual
process is especially important when introducing new
technologies and work flows into everyday busy clinical
practice to ensure the endorsement from clinicians [22].
Likewise, the time in which this study was conducted
allowed for inclusion of patients undergoing immunother-
apy with a PD-L1 inhibitor, pembrolizumab, in a standard
care setting. Thus, the current and previously reported
study 1 [17] are among the first to report real-world data
from urothelial cancer patients undergoing immunother-
apy in a standard care setting [23]. An important note on
the length of this study is of course that in larger cancer
institutions the described item selection process is pos-
sible over a shorter period of time allowing for application
of this process without granting up to two years for the
planning.
Despite the attempt to deliver a thorough mixed
methods approach to the PRO-CTCAE item selec-
tion process, some limitations need to be addressed.
First, collection and use of real-world PROs as one
of the methods in this study seems intuitive and in
respect with the patients exposed to the final ques-
tionnaire product. However, the limited number of
patients contributing to study 1 introduce the risk of
achieving data with a low degree of reliability. This
consideration also has relevance in relation to the
focus groups including only a limited number of
specialist nurses and physicians. To some extent, this
is addressed by the mixed methods design. One may
also add, that the application of the Delphi method
in the focus groups would, potentially, have resulted
in more reliable data [24]. Also, given the limited
number of patients in immunotherapy participating
in study 2, the level of information from this part of
the process may be insufficient. This issue is sought
weighed up by the RCT’s and focus groups given in-
formation on patients in immunotherapy but should
nevertheless not be overlooked. Last, selection bias
in the PRO items included arise from the fact, that a
number of patients did not participate and non-re-
sponders in survey studies are reported to have a
poorer prognosis [25–27]. This group of non-partici-
pants may have other preferences/problems com-
pared to participants and we have no information on
non-participants.
Conclusions
This study presents a transferable set of PROs to
apply in a bladder cancer population undergoing
medical oncological treatment. A methodological ap-
proach to item selection is vital for an effect on clin-
ical outcomes and the effects of the chosen PROs in
this study will be tested in a forthcoming randomized
trial. The systematic selection process displayed here
may assist the planning of future research or support
clinical implementation in not only the bladder can-
cer population but across all cancer diseases.
Additional file
Additional file 1: PRO-CTCAE ITEM SELECTION FOR PILOT STUDY.
(DOCX 42 kb)
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Table 2 Final PRO-CTCAE Item Selection Process (Continued)
Focus group interviews Overall PRO-CTCAE
symptoms grade 2-4 for
29 patients* (listed by
falling frequency, %)
PRO-CTCAE symptoms
grade 2-4 in relation
to hospital admission
(patients receiving
n=13 chemo- / n=7
immunotherapy)**
Final included
PRO-CTCAE
symptom
Nurses, n=3 Doctors, n=4
Vomiting Vomiting (2) Vomiting
Memory (1) Memory (1)
Concentration (1) Concentration (1)
Weight loss
Stomatitis
aOf the 30 patients enrolled in study 1, only 29 initiated treatment
bOf the 27 patients in study 2 experiencing hospital admission, only 20 (13 chemotherapy / 7 immunotherapy) patients had a completed questionnaire in relation
to the hospital admission
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